CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$97.09M, compared with -$41.45M a year earlier.

Context

  • Net debt amounted to 92.1% of total assets at the end of Q1 FY2026, up 26.0 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -134.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$97.09M+9.7% QoQ
Last fiscal yearDec 2025
-$107.54M-94.2% YoY
Year agoMar 2025
-$41.45M-134.2% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-134.2%——
1 year-94.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(107.54M) USD
Year-over-year change
-94.2%

Net Debt vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -134.2% is the 6th highest of 9, against a peer median of -73.3%.
  • Net debt amounts to 92.1% of total assets for CAMP, versus a peer median of 34.8%.
CAMP Competitors
Net Debt for CAMP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ATYRaTyr Pharma, Inc.Mar 2026$1.69M USD-35.6%-6.0%2.1%
HYFTMindWalk Holdings Corp.Jan 2026-CA$10.63M CAD-81872.4%—45.9%
ALXOALX Oncology Holdings Inc.Mar 2026-$27.07M USD-154.3%—15.2%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026-$31.65M USD+11.2%—29.4%
UNCYUnicycive Therapeutics, Inc.Mar 2026-$36.43M USD-91.0%—56.6%
PMVPPMV Pharmaceuticals, Inc.Mar 2026-$38.84M USD+22.7%—40.2%
VXRTVaxart, Inc.Mar 2026-$42.78M USD-260.4%—23.8%
BMEABiomea Fusion, Inc.Mar 2026-$43.45M USD-55.5%—93.7%
CAMPCAMP4 Therapeutics CorporationMar 2026-$97.09M USD-134.2%—92.1%
Peer median (excluding CAMP) —-73.3%-6.0%34.8%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents91.11M83.19M38.38M64.04M109.52M
Short-term Investments00000
Net Receivables58.59M678K442K108K155K
Inventory20.18M0000
Other Current Assets23.71M205K245K211K4.42M
Total Current Assets193.59M84.41M40.01M66.38M114.1M
Property, Plant & Equipment (Net)50.06M16.8M13.31M10.3M2.74M
Goodwill94M0000
Intangible Assets33.01M0000
Long-term Investments24.34M000894K
Tax Assets4.23M0000
Other Non-current Assets3.05M1.35M1.62M1.62M83K
Total Non-current Assets208.7M18.14M14.93M11.92M3.71M
Total Assets402.29M102.55M54.95M78.31M117.81M
Account Payables30.78M2.15M1.04M1.21M182K
Short-term Debt7.74M000286K
Tax Payables00000
Deferred Revenue32.4M00385K9.39M
Other Current Liabilities23.96M1.78M2.34M3.2M5.66M
Total Current Liabilities94.88M7.95M7.81M9.6M15.51M
Long-term Debt201.43M0001.69M
Deferred Tax Liabilities208K0000
Deferred Revenue (Non-current)14.49M0008.11M
Other Non-current Liabilities11.1M162.11M162.23M2K44.79M
Total Non-current Liabilities227.23M172.13M170.87M5.57M54.59M
Total Liabilities322.11M180.08M178.68M15.16M70.1M
Common Stock359K1K1K2K6K
Retained Earnings(156.78M)(110.67M)(159.96M)(211.75M)(292.16M)
Accumulated OCI(2.44M)0000
Other Stockholders Equity239.04M0000
Minority Interest00000
Total Equity80.18M(77.53M)(123.73M)63.14M47.7M
Total Debt209.17M12.4M11.69M8.65M1.97M
Net Debt118.05M(70.8M)(26.69M)(55.39M)(107.54M)

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.